Abstract
Bristol-Myers Squibb will report second-quarter 2026 results on July 30, 2026 Pre-Market, with investor attention centered on revenue resilience around new launches and lifecycle brands, margin progression relative to recent levels, and near-term pipeline catalysts expected to shape guidance tone into the second half of the year.Market Forecast
Consensus for the current quarter points to total revenue of 11.74 billion US dollars, implying approximately 3.22% year-over-year growth, alongside an adjusted EPS estimate of about 1.59, up an estimated 48.14% year over year; EBIT is modeled at 4.16 billion US dollars, up an estimated 51.97% year over year. Forecast data do not specify gross profit margin or net margin for the current quarter. Operationally, the core commercial portfolio is expected to provide steady contributions, with stable demand in cardiovascular and oncology therapies and incremental lift from new and recently expanded labels. Within emerging growth drivers, cell therapy and cardiomyopathy assets are watched closely; last quarter, the company recorded 411.00 million US dollars from Breyanzi and 314.00 million US dollars from Camzyos, while year-over-year growth by product was not disclosed in the dataset used for this preview.Last Quarter Review
In the previous quarter, Bristol-Myers Squibb delivered revenue of 11.49 billion US dollars (up 2.57% year over year), a gross profit margin of 70.34%, GAAP net profit attributable to shareholders of 2.68 billion US dollars, a net profit margin of 23.30%, and adjusted EPS of 1.58 (down 12.22% year over year). A key highlight was a broad beat versus consensus, with revenue exceeding estimates by about 0.58 billion US dollars and adjusted EPS exceeding consensus by about 0.16, while net profit increased 146.27% quarter on quarter. Main business execution remained anchored by flagship therapies: Eliquis contributed 4.14 billion US dollars, Opdivo 2.15 billion US dollars, Orencia 818.00 million US dollars, Yervoy 651.00 million US dollars, Reblozyl 555.00 million US dollars, Pomalyst 513.00 million US dollars, Breyanzi 411.00 million US dollars, Revlimid 349.00 million US dollars, and Camzyos 314.00 million US dollars, with total company revenue up 2.57% year over year in aggregate.Current Quarter Outlook
Core Franchise: Eliquis and Opdivo
The quarterly setup is anchored by the durability of Eliquis and Opdivo, which together accounted for roughly half of last quarter’s revenue. Eliquis (apixaban) posted 4.14 billion US dollars last quarter, underscoring consistent demand in stroke prevention and venous thromboembolism settings. For the current quarter, consensus implies that continued volume strength and broad cardiovascular usage should help offset any seasonal variations, supporting the topline even as overall company growth remains contained at a low-single-digit rate. Oncology remains a second pillar: Opdivo (nivolumab) generated 2.15 billion US dollars last quarter, and incremental regulatory progress—such as the recent European clearance for an Opdivo-based combination in advanced classical Hodgkin lymphoma—adds breadth to its label set. While exact product-level quarter-on-quarter trajectories are not provided in the forecast dataset, commentators anticipate that incremental label expansions and diversified usage across tumor types will help Opdivo deliver a steady contribution. Together, these two franchises frame the company’s earnings stability in the quarter being reported, with aggregate consensus forecasting revenue growth of 3.22% year over year and materially higher adjusted EPS on operating leverage and mix.Emerging Growth Drivers: CELMoD and Cell Therapy
The second-quarter narrative also features momentum across the hematology portfolio and cell therapy. Reblozyl booked 555.00 million US dollars last quarter, and while the dataset does not include product-level year-over-year growth, market interest in the anemia space and label breadth supports expectations for continued adoption. Within cell therapy, Breyanzi delivered 411.00 million US dollars last quarter; given ongoing physician familiarity, manufacturing scaling, and competitive positioning among CAR-T options, observers are watching whether quarterly run-rates continue to step higher from this baseline. Beyond currently marketed assets, management developments around the CELMoD platform are becoming more visible. In mid-July, the company said the US regulator accepted a new drug application for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, assigning a target action date in 2027. Along with iberdomide—expected to face a regulatory decision in the near term—these assets shape sentiment for the hematology franchise and could be catalysts for second-half commentary even if they have minimal near-term revenue impact. Analysts tracking the quarter point out that steady in-line results in Q2 set up a “pivotal” second half of the year as these programs approach key milestones.Operating Metrics and Margin Considerations
Consensus embeds an adjusted EPS of about 1.59 for the quarter, translating to 48.14% year-over-year growth, far outpacing the expected 3.22% revenue growth. The last reported gross margin of 70.34% provides a reference point; while there is no explicit margin forecast in the dataset, investors will parse whether mix and cost controls maintain margins near recent levels. On operating lines, EBIT is modeled at 4.16 billion US dollars, up 51.97% year over year, suggesting leverage from cost discipline and product mix. Relative to the prior quarter’s net margin of 23.30%, investors will look for signals that the margin trajectory is stabilizing or improving as branded drivers offset known revenue headwinds in legacy hematology. Absent explicit guidance for gross or net margins this quarter, much of the interpretation will hinge on management’s qualitative commentary.Pipeline and Near-Term Catalysts
Management’s second-half setup is framed by a cluster of clinical and regulatory events. External commentary highlights upcoming milestones for the anti-stroke candidate milvexian and an Alzheimer’s program referred to in recent notes as Cobenfy, with the mix of cardiovascular and neuroscience catalysts drawing attention to the breadth of late-stage options. While these programs are unlikely to materially move Q2 results, they are expected to shape the guidance tone, with consensus leaning toward in-line performance now and a busier catalyst calendar later in the year. The company’s recently announced expansion of its partnership with a leading AI infrastructure provider to build an industry-scale computing platform for drug research adds a technology-forward dimension to R&D productivity. Investors will assess whether incremental AI capabilities translate to better target identification, trial design, and cycle times, though any tangible financial contribution would be longer dated. In the nearer term, management’s second-quarter remarks on regulatory filing cadence, program prioritization, and capital allocation remain central to how investors handicap the trajectory into the third and fourth quarters.Capital Returns and Balance Sheet Signals
Dividend continuity is a background support for the equity story into the quarter. The company kept its quarterly dividend at 0.63 per share with a recent record and payment schedule, signaling confidence in cash generation and near-term financial stability. With last quarter’s revenue beat and robust EBIT, balance sheet flexibility appears sufficient to support ongoing shareholder returns while funding late-stage trials and selective business development. Investors will listen for confirmation that operating cash flow remains on track with internal expectations, and for any changes in capital deployment priorities given the intensifying late-stage pipeline.What Can Move the Stock on Print
The primary stock drivers around the print include headline revenue versus the 11.74 billion US dollars consensus, adjusted EPS versus the 1.59 consensus, and any surprises in operating margin progression. Product color will be scrutinized: commentary around Eliquis volume trends and Opdivo adoption across newly approved indications may influence how investors extrapolate to the second half. Updates around the hematology portfolio—particularly any indications of sustained Reblozyl momentum or a continued ramp in Breyanzi—could inform the mix outlook. Finally, pipeline timing is a swing factor: if management strengthens timelines for milvexian or provides new visibility on the Alzheimer’s effort, sentiment may skew more constructive into the back half even if Q2 itself is largely in line.Analyst Opinions
The balance of recent published views tilts neutral-to-cautious: among sampled opinions, approximately 2 of 7 are bullish and 5 of 7 are neutral/hold, indicating that the majority stance is cautious ahead of a catalyst-rich second half. Institutions expressing this view include RBC Capital Markets with a Sector Perform rating and a 60 US dollars price target, noting that Q2 is likely “solid” and largely in line while the second half contains the more consequential milestones. Additional neutral or hold stances came from Goldman Sachs, which maintained a 61 US dollars target while citing near-term uncertainties balanced by longer-term pipeline potential, and from BMO Capital, Scotiabank, and Berenberg, each maintaining hold/neutral ratings with 60 US dollars targets in recent months. On the bullish side, Jefferies reiterated a Buy rating with a 73 US dollars target, and Piper Sandler maintained a Buy with a 75 US dollars target, both emphasizing the value of pipeline optionality and continued commercial execution; however, these were fewer than the neutral views. One major theme across the majority opinions is that, despite dependable contributions from Eliquis and Opdivo, investors remain focused on execution against hematology and neuroscience catalysts and on how management guides the earnings bridge into 2027–2028 as product lifecycles evolve.From the cautious perspective, the thesis for the upcoming report is that an in-line revenue outcome around 11.74 billion US dollars, combined with commentary consistent with recent trends, is sufficient to keep estimates stable but not to change positioning meaningfully until catalysts crystalize. Analysts in this camp point to the prior quarter’s 70.34% gross margin and 23.30% net margin as healthy baselines but would like to see evidence of margin durability as mix shifts continue within the portfolio. They also highlight that last quarter’s 1.58 adjusted EPS, down 12.22% year over year, underscores the need for operating leverage to re-accelerate earnings growth—something consensus expects in Q2, with a modeled 48.14% year-over-year increase in adjusted EPS. Confirmation that this inflection is tracking will be a focal point.
Cautious analysts further note that product-level breakouts for year-over-year growth will help clarify the sustainability of newer contributors like Reblozyl, Breyanzi, and Camzyos, which collectively delivered 1.28 billion US dollars last quarter. Absent explicit product growth rates in the quarter’s forecasts, the onus is on management to articulate demand drivers and endurance of uptake curves, particularly in light of second-half regulatory events. The cautious majority also underscores the significance of the AI partnerships and digital initiatives as potential medium-term enablers but tempers near-term expectations, preferring to see these capabilities translate into tangible cycle-time or cost improvements over subsequent reporting periods.
In sum, the prevailing institutional stance heading into July 30, 2026 is neutral: expectations cluster around an in-line revenue print and a solid adjusted EPS outcome, with stock reaction likely to depend on product color, any surprises on margins, and the clarity of second-half catalyst timing. Should management provide sharpened visibility on the CELMoD pathway and offer incremental conviction around cardiovascular and neuroscience milestones, sentiment could improve even without a large top-line surprise. Conversely, if quarterly commentary is light on timing detail or if core franchise updates imply a slower than expected ramp in newer assets, the neutral-to-cautious majority would likely maintain its stance. The quarter therefore functions as a checkpoint: validation of the 3.22% revenue growth outlook and the 1.59 adjusted EPS consensus, paired with credible second-half execution frames, is what most neutral-rated institutions seek before revising their views.